First results with THR-149 show promise in treatment of diabetic macular edema

First results with THR-149, a bicyclic peptide inhibitor that targets plasma kallikrein, showed safety and efficacy in treating patients with diabetic macular edema, according to a specialist speaking at the virtual Euretina congress.“THR-149 is a highly potent, selective and stable peptide developed by Oxurion in partnership with Bicycle Therapeutics. It targets a VEGF-independent pathway,

Read the full article here

Related Articles